Dr.ย Linย Shen
MD, Chief Physician, Professor of Oncology
Director, Department of Gastrointestinal Oncology
corporate_farePeking University Cancer Hospital, Beijing
Lin Shen
MD, Chief Physician, Professor of Oncology
Prof. Lin Shen is a leading gastrointestinal medical oncologist with more than four decades of clinical and research experience in digestive-system cancers. She is Director of the Department of Gastrointestinal Oncology and Director of the Phase I Clinical Trial Ward at Peking University Cancer Hospital & Institute in Beijing, and Director of the Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumors.
Prof. Shen is internationally recognised for her work in gastric cancer, with a focus on precision treatment of advanced and difficult-to-treat disease. Her clinical and research interests span chemotherapy, HER2-targeted therapy, PD-1 and PD-L1 immunotherapy, biomarker-guided treatment, early-phase drug development, and emerging cellular therapies such as CLDN18.2-directed CAR T-cells. She has served as leading principal investigator for more than 100 national and international clinical studies, contributed to 16 approved drug indications, and helped shape updates to more than 40 clinical-practice guidelines. She has published over 250 papers as first or corresponding author in journals including Nature, The Lancet, JAMA, BMJ and Nature Medicine. She graduated from Xuzhou Medical College in 1984 and Beijing Medical University in 1995, and trained at the U.S. National Institutes of Health in 2000.
Prof. Shen reviews complex gastrointestinal cancer cases referred from abroad. CancerFax coordinates record review, appointment scheduling, interpreter support, and travel logistics for international patients seeking her opinion in Beijing.
Why Consult Prof. Lin Shen?
Prof. Shen brings four decades of focused gastrointestinal oncology expertise and direct access to early-phase trials and advanced therapies at one of China's leading cancer centres.
Areas of Specialization
Precision treatment of advanced gastrointestinal cancers
Prof. Shen's practice centres on biomarker-guided systemic therapy for gastric and other gastrointestinal cancers, with deep expertise in HER2-targeted treatment, PD-1 and PD-L1 immunotherapy, CLDN18.2-directed strategies, and early-phase clinical trials.
Gastric & GI Systemic Therapy
Stage-appropriate, pathology-driven systemic treatment for localized, recurrent and metastatic gastric and gastroesophageal junction cancer.
- arrow_rightFirst-line and later-line chemotherapy for advanced gastric cancer
- arrow_rightCombination regimens for gastroesophageal junction cancer
- arrow_rightTreatment planning after standard therapy has stopped working
- arrow_rightAnti-HER2 therapy for HER2-positive gastric cancer
- arrow_rightAnti-HER2 therapy combined with PD-1 or PD-L1 inhibitors
- arrow_rightMultimodal prediction of response to anti-HER2 treatment
- arrow_rightCLDN18.2-directed treatment approaches for gastric cancer
- arrow_rightPatient selection by CLDN18.2 expression status
Immunotherapy
Checkpoint inhibitor therapy and biomarker-guided immunotherapy for gastrointestinal cancers.
- arrow_rightAnti-PD-1 and anti-PD-L1 therapy for gastric and GI cancers
- arrow_rightBiomarker evaluation to help predict immunotherapy response
- arrow_rightImmunotherapy combined with chemotherapy
- arrow_rightImmunotherapy combined with targeted therapy
Cellular & Precision Therapy
Cell therapy research and molecular-profiling-guided treatment selection for solid tumours.
- arrow_rightPhase I research on CT041, a CLDN18.2-directed CAR T-cell therapy
- arrow_rightEvaluation in previously treated CLDN18.2-positive digestive cancers
- arrow_rightMolecular profiling to guide treatment selection
- arrow_rightEarly-phase clinical trial evaluation for advanced disease
Procedures & Treatments Performed
Systemic and precision oncology interventions for GI cancers
Systemic Chemotherapy
Medical OncologyStage-appropriate chemotherapy and combination regimens for gastric and gastrointestinal cancers.
HER2-Targeted Therapy
Targeted TherapyAnti-HER2 treatment for HER2-positive gastric cancer, alone or with immunotherapy.
Immunotherapy Administration
Medical OncologyPD-1 and PD-L1 checkpoint inhibitor therapy for gastrointestinal cancers.
Cell Therapy & Early-Phase Trials
Complex DiseaseInvestigational cellular therapies and Phase I trial access for advanced digestive-system cancers.
Molecular Diagnostics & Staging
DiagnosisBiomarker testing and staging to guide precision treatment planning.
Second Opinion Consultations
Second OpinionIndependent expert review of pathology, imaging and treatment history for complex GI cancers.
Research & Publications
Clinical trial leadership and peer-reviewed contributions in GI oncology
Prof. Shen has dedicated her career to translational research and precision treatment in gastrointestinal oncology, spanning gastric cancer, biomarker-guided therapy, early-phase drug development, immunotherapy and cellular therapy for solid tumours.
As Director of the Phase I Clinical Trial Ward, Prof. Shen's work means eligible patients may be able to access early-phase and investigational therapies through CancerFax-coordinated review and referral.
Education & Training
Prof. Shen trained at leading Chinese medical institutions and undertook international research training in gastrointestinal oncology.
Clinical Experience
More than four decades in gastrointestinal oncology at Peking University Cancer Hospital & Institute, with senior leadership across clinical care, research and early-phase trials.
Languages & International
Prof. Shen consults in the following languages.
CancerFax coordinates professional medical interpreters for patients from Russia, the CIS region, the Middle East, Southeast Asia and beyond.
CancerFax provides certified medical interpreters for international patients, so language is never a barrier to consulting Prof. Shen.
How CancerFax Helps You Access Dr. Lin Shen
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Lin Shen's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Lin Shen's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Lin Shen before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Lin Shen's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Lin Shen's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Lin Shen's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Lin Shen
Yes. Prof. Shen reviews complex gastrointestinal cancer cases referred from outside China. CancerFax coordinates the full process for international patients, including medical record review, appointment scheduling, interpreter support, visa letters, and travel logistics in Beijing.
Prof. Shen specialises in gastric and gastroesophageal junction cancer, including HER2-positive disease. She also treats esophageal cancer, colorectal cancer, pancreatic cancer, gastrointestinal stromal tumours (GIST), gastrointestinal neuroendocrine tumours, and biliary tract cancers.
Submit your medical reports, pathology findings, imaging and treatment history through CancerFax using the 'Send Your Reports' button. Our oncology team prepares a structured summary and coordinates the consultation or preliminary review with Prof. Shen's team at Peking University Cancer Hospital.
Depending on the stage, pathology and biomarker profile, options may include chemotherapy, HER2-targeted therapy for HER2-positive disease, PD-1 or PD-L1 immunotherapy, combination approaches, and CLDN18.2-directed strategies. Eligible patients may also be considered for early-phase clinical trials. All treatment options require expert medical review of complete investigations.
Yes. Prof. Shen is Director of the Phase I Clinical Trial Ward and Director of the Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumors. Her team has reported Phase I findings for CT041, an investigational CLDN18.2-directed CAR T-cell therapy. CancerFax can help assess whether you may be eligible for relevant trials in China.
This is a common reason patients seek her opinion. Prof. Shen has extensive experience with difficult and recurrent gastrointestinal cancers, including biomarker-guided precision treatment and access to early-phase trials. A full review of your investigations is needed before any treatment pathway can be considered.
Connect with Lin Shen Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.